BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.01) EPS for the quarter, Zacks reports.
BioNxt Solutions Price Performance
Shares of BNXTF stock traded down $0.02 during trading hours on Tuesday, reaching $0.17. 3,835 shares of the company’s stock were exchanged, compared to its average volume of 5,019. The company’s 50 day moving average is $0.23 and its two-hundred day moving average is $0.30. The company has a market cap of $22.75 million, a P/E ratio of -3.34 and a beta of 0.85. BioNxt Solutions has a 1 year low of $0.10 and a 1 year high of $0.51.
BioNxt Solutions Company Profile
BioNxt Solutions Inc. is a biotechnology company developing drug-delivery technologies and pharmaceutical products. Its work includes sublingual dissolving films and other formulations intended to make medicines easier to administer and potentially improve how they are delivered. The company’s development programs include a sublingual formulation of cladribine, a medicine used to treat multiple sclerosis. BioNxt is also pursuing other drug-delivery and therapeutic projects; its products are in development rather than established as marketed treatments.
Read More
- Five stocks we like better than BioNxt Solutions
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for BioNxt Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNxt Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
